Splenectomy — Surgical Removal of the Spleen — Cost, Top Hospitals & Success Rates | MyMedicPlus

Splenectomy — the complete surgical removal of the spleen — is one of the most commonly performed abdominal procedures in both elective and emergency settings. The spleen is a fist-sized lymphoid organ in the left upper quadrant of the abdomen responsible for filtering blood, removing senescent red cells, and mounting immune responses against encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and Neisseria meningitidis. Its removal therefore carries lifelong immunological consequences that must be proactively managed.

Splenectomy is performed in two broad clinical scenarios. Elective splenectomy is planned in advance for haematological conditions (immune thrombocytopenic purpura, hereditary spherocytosis, thalassaemia, haemolytic anaemias), symptomatic splenomegaly, splenic cysts or abscesses, and staging or treatment of haematological malignancies. Emergency splenectomy is required for traumatic splenic injury classified as American Association for the Surgery of Trauma (AAST) Grade IV–V, where non-operative management or splenic artery embolisation has failed or is not feasible due to haemodynamic instability.

The laparoscopic approach is now the gold standard for elective cases, offering faster recovery, reduced blood loss, and lower wound complication rates compared with open surgery. For massively enlarged spleens (splenomegaly >20 cm or weight >1 kg), a hand-assisted laparoscopic splenectomy (HALS) technique balances minimally invasive benefits with the tactile control needed for safe hilar dissection. A standard 5-port laparoscopic configuration is used for most cases, with the patient in a right lateral decubitus position and the spleen mobilised medially after division of the short gastric vessels and splenocolic ligament before secure ligation of the splenic hilar vessels.

Intraoperative decisions include whether to place a closed-suction drain. Current evidence — including systematic reviews and the Cochrane analysis on drainage after elective laparoscopic splenectomy — supports no routine drain placement in uncomplicated elective cases, as drainage does not reduce the rate of subphrenic abscess and increases infection risk.

Splenectomy is indicated across a wide range of haematological, oncological, traumatic, and structural conditions. The decision to operate is guided by clinical severity, response to medical therapy, and the balance of surgical risk against disease burden.

• Immune Thrombocytopenic Purpura (ITP): Splenectomy achieves sustained remission in 60–70% of steroid-refractory or relapsing adult ITP cases. The spleen is both the primary site of platelet autoantibody production and destruction. Splenectomy is considered second-line when first-line corticosteroids and IVIG fail.
• Hereditary Spherocytosis: Surgical removal abolishes haemolytic crises in patients with moderate-to-severe disease, although partial splenectomy is preferred in children to preserve some immune function.
• Thalassaemia Major and Sickle Cell Disease: Hypersplenism causing transfusion burden may warrant splenectomy, particularly in thalassaemia intermedia with painful splenomegaly or sequestration crises.
• Haematological Malignancies: Lymphoma with splenic involvement, hairy cell leukaemia (pre-targeted therapy era), and myelofibrosis-related massive splenomegaly may require splenectomy for disease control or symptom relief.
• Splenic Trauma (AAST Grade IV–V): Stellate lacerations extending to the hilum (Grade IV) or completely shattered spleens (Grade V) with haemodynamic instability require urgent operative intervention. Grade I–III injuries in stable patients are typically managed non-operatively.
• Splenic Abscess: Multiloculated abscesses not amenable to percutaneous drainage, often due to fungal infection in immunocompromised patients, require splenectomy.
• Splenic Cysts and Tumours: Large symptomatic pseudocysts, parasitic (echinococcal) cysts, and primary splenic tumours are treated with splenectomy or partial resection.
• Gaucher Disease: Enzyme replacement therapy has largely replaced splenectomy, but massive symptomatic splenomegaly with mechanical complications remains a surgical indication in resource-limited settings.

Patient selection for splenectomy involves a structured pre-operative assessment to weigh the magnitude of the indication against surgical risk and the permanent immunological consequences of asplenia.

Elective candidacy criteria include:

• ITP with platelet count persistently below 30,000/µL despite first- and second-line therapy, or symptomatic bleeding episodes
• Hereditary spherocytosis with Hb <8 g/dL, growth retardation, or recurrent aplastic crises — ideally deferred until age 6 or older to preserve early immune education
• Thalassaemia with annual transfusion requirements exceeding 200–250 mL/kg/year, or symptomatic hypersplenism
• Lymphoma staging (now largely superseded by PET-CT) or symptomatic splenic disease unresponsive to systemic therapy
• Fitness for general anaesthesia: patients with severe cardiorespiratory comorbidity may be better managed non-surgically

Emergency candidacy (trauma):

• AAST Grade IV–V splenic injury with haemodynamic instability (systolic BP <90 mmHg, base deficit >6, or transfusion >4 units in 24 hours) unresponsive to resuscitation
• Failed non-operative management or splenic artery embolisation
• Associated hollow viscus injuries requiring laparotomy

Patients with portal hypertension, severe coagulopathy, or spleen weight above 3 kg require specialised planning. Pre-operative vaccination is mandatory for elective cases (ideally 2 weeks before surgery). For emergency splenectomy, vaccination is administered post-operatively before hospital discharge.

The choice of surgical approach is determined by the indication, splenic size, body habitus, previous abdominal surgery, and urgency.

Laparoscopic Splenectomy (Standard — 5-Port Technique): The patient is positioned in right lateral decubitus at 45–60°. Five trocars are placed: a 10–12 mm umbilical camera port, two 5 mm left subcostal working ports, a 5 mm epigastric port for liver retraction, and a 10–12 mm left flank extraction port. The short gastric vessels are divided with an energy device (LigaSure or Harmonic scalpel), the splenocolic and splenorenal ligaments are divided, and the hilar vessels are individually ligated or controlled with a laparoscopic linear vascular stapler. The spleen is placed in a retrieval bag and morcellated for extraction, or a small extension of the port site is made for intact removal. Operative time is typically 60–120 minutes.

Hand-Assisted Laparoscopic Splenectomy (HALS): Indicated for massive splenomegaly (>20–25 cm). A 7–8 cm hand port (GelPort) is placed in the midline, allowing tactile control of the hilum and facilitating safe vascular division in enlarged, friable spleens. Blood loss is reduced compared with open surgery while accommodating organ size.

Open Splenectomy: A midline or left subcostal (Kocher) incision is used. This remains the approach of choice for haemodynamically unstable trauma, intraoperative laparoscopic conversion, and cases with extensive adhesions. The hilar vessels are ligated in continuity before splenic mobilisation. Mortality in trauma open splenectomy is 3–5%, primarily reflecting the severity of associated injuries rather than the procedure itself.

Splenic Artery Embolisation (SAE): Used as an adjunct to non-operative management of Grade III–IV trauma or as a bridge to planned surgery in ITP/hypersplenism to reduce spleen size and platelet consumption pre-operatively. Not a definitive alternative to splenectomy for Grade V injuries.

Partial Splenectomy: Preserves splenic remnant for immune function; used in children with hereditary spherocytosis and selected benign cysts. Technical challenge is controlling segmental hilar vessels with risk of post-operative torsion of the remnant.

When performed for the right indication, splenectomy offers substantial clinical benefits that can be life-changing or life-saving:

• Haematological Remission: In ITP, splenectomy achieves durable platelet response (>50,000/µL) in 60–70% of adults, with complete response in many, reducing bleeding risk and dependence on immunosuppression. For hereditary spherocytosis, haemolysis ceases post-operatively in virtually all cases.
• Resolution of Symptomatic Splenomegaly: Relief of early satiety, left upper quadrant pain, and mechanical discomfort is immediate and dramatic in patients with massively enlarged spleens from lymphoma, myelofibrosis, or thalassaemia.
• Reduction in Transfusion Burden: In thalassaemia with hypersplenism, post-splenectomy transfusion requirements decrease by 30–50% in many patients, improving quality of life and reducing iron loading.
• Haemorrhage Control in Trauma: Emergency splenectomy is definitively haemostatic in splenic injury, removing the source of life-threatening intra-abdominal haemorrhage when non-operative strategies are not feasible.
• Minimally Invasive Recovery: The laparoscopic approach enables discharge within 24–48 hours, return to light activities within 2 weeks, and full recovery within 4–6 weeks, compared with 6–8 weeks for open surgery.
• Oncological Control: In select haematological malignancies, splenectomy reduces tumour burden, corrects cytopenias caused by splenic sequestration, and allows more effective systemic therapy.

Splenectomy carries both operative and long-term risks that require lifelong patient education and vigilance.

Intraoperative Risks:

• Haemorrhage from short gastric vessels, hilar injury, or accessory splenic vessels (present in 15–30% of patients)
• Injury to adjacent structures: tail of pancreas (leading to fistula or pseudocyst), stomach, left colon, diaphragm
• Conversion from laparoscopic to open (2–5% elective; higher with massive splenomegaly)

Early Post-operative Complications:

• Subphrenic abscess (1–4%), particularly if pancreatic injury occurred
• Left pleural effusion or atelectasis (common, usually self-limiting)
• Portal or splenic vein thrombosis (5–10%), particularly in myeloproliferative disorders — requires anticoagulation
• Wound infection, haematoma, ileus

Long-term Risk — Overwhelming Post-Splenectomy Infection (OPSI): This is the most feared complication of asplenia. OPSI is a fulminant sepsis caused predominantly by encapsulated bacteria (pneumococcus 50%, Hib, meningococcus) with a mortality of 50–70% if untreated. Lifetime risk is 3–5% (higher in children and haematological malignancy). Prevention requires:

• Vaccination: pneumococcal (PCV20 or PPSV23), Hib, meningococcal ACWY and B — given pre-operatively (elective) or post-operatively before discharge (emergency)
• Prophylactic penicillin V 250 mg twice daily (or amoxicillin 250 mg) lifelong — in accordance with British Society for Haematology (BSH) guidelines 2022
• Emergency antibiotic supply: patients carry an emergency supply of co-amoxiclav and an emergency steroid/antibiotic action card to present to emergency departments
• Annual influenza vaccination; regular pneumococcal booster per schedule

Other Long-term Concerns: Thrombocytosis (platelet count may rise to 800,000–1,200,000/µL post-operatively); venous thromboembolism risk (prophylaxis with LMWH for 4 weeks post-discharge is recommended); pulmonary hypertension (rare, more common in hereditary haemolytic anaemias).

Structured follow-up after splenectomy is not merely routine — it is an ongoing programme of infection prevention that is literally life-saving for asplenic patients.

Immediate Post-operative Period (0–6 weeks):

• FBC monitoring: platelet count peaks at 10–14 days; if >1,000,000/µL consider low-dose aspirin
• Portal/mesenteric vein thrombosis screening: ultrasound doppler at 4–6 weeks in high-risk patients (myeloproliferative disorders, polycythaemia)
• Wound review at 7–10 days; staple removal if open approach
• Commence prophylactic penicillin V if not already started

Vaccination Schedule: If not vaccinated pre-operatively, administer at 2 weeks post-op when immune recovery allows better antibody response:

• Pneumococcal: PCV20 (preferred) or PCV13 followed by PPSV23 at 8 weeks; PPSV23 booster every 5 years
• Hib: single dose (if not previously immunised as adult)
• Meningococcal ACWY: 2 doses 2 months apart; MenB: 2 doses 1 month apart
• Annual influenza vaccine

Long-term Follow-up:

• Annual review with GP or haematologist to check vaccination status, reinforce OPSI awareness, and review antibiotic prophylaxis compliance
• Patients should carry an asplenia alert card (or medical alert bracelet) at all times
• Any febrile illness ≥38°C should be treated as a medical emergency — patients must seek urgent medical attention and take their emergency antibiotic supply while travelling to hospital
• Travel precautions: malaria prevention is critical in asplenic patients (higher risk of severe falciparum malaria); avoid travel to high-risk areas if possible; meticulous prophylaxis if unavoidable

The cost of splenectomy varies significantly based on surgical approach, indication (elective vs emergency), hospital setting, and country of treatment.

• Surgical Approach: Laparoscopic splenectomy typically costs 20–30% more than open surgery in terms of equipment (disposable trocars, linear staplers, energy devices, specimen retrieval bags) but reduces overall hospital expenditure through shorter stays and faster recovery.
• Elective vs Emergency: Emergency splenectomy costs are substantially higher due to ICU admission, blood transfusion, damage-control surgery needs, and longer hospitalisation (average 7–14 days in trauma).
• Country and Hospital:
  • India: USD 2,000–5,000 (private tertiary hospital, laparoscopic)
  • Thailand: USD 4,000–8,000
  • United Kingdom (NHS): Tariff approximately GBP 5,000–8,000 (HRG code JA03Z)
  • United States: USD 15,000–40,000 (insured) — uninsured costs significantly higher
  • Singapore: USD 8,000–15,000
• Post-operative Costs: Vaccination programme (USD 200–600), long-term prophylactic antibiotics (inexpensive generic penicillin V), annual haematology review
• Insurance Coverage: Splenectomy for trauma or haematological disease is almost universally covered by health insurance and national health systems. Elective splenectomy for cosmetic or unvalidated indications is not covered.

Medical travel to India, Thailand, Turkey, and Eastern Europe offers significant savings for elective procedures, with outcomes comparable to Western centres in accredited hospitals. Always verify hospital accreditation (JCI, NABH) and surgeon subspecialty experience.

Given the lifelong immunological consequences of asplenia, alternatives to splenectomy are actively sought, particularly for children and young adults. The availability and efficacy of alternatives depend on the underlying indication.

• Non-operative Management (Splenic Trauma): AAST Grade I–III injuries in haemodynamically stable patients are successfully managed non-operatively in 80–95% of cases. Splenic artery embolisation (SAE) extends non-operative management to selected Grade IV injuries, preserving splenic parenchyma and immune function.
• Thrombopoietin Receptor Agonists (TPO-RA) for ITP: Eltrombopag and romiplostim are second-line agents that stimulate platelet production and have changed the management of ITP, significantly reducing the proportion of patients who require splenectomy. However, TPO-RAs require continuous therapy and are expensive.
• Rituximab for ITP and Autoimmune Haematological Disorders: Anti-CD20 monoclonal antibody achieves sustained remission in 40–60% of ITP patients, deferring or avoiding splenectomy. Combination rituximab + dexamethasone is used in some protocols.
• Partial Splenectomy: In hereditary spherocytosis and selected benign splenic lesions, resection of 80–90% of splenic volume reduces haemolysis while preserving immune-active residual tissue. Long-term follow-up data show lower OPSI risk than total splenectomy.
• Splenic Artery Embolisation: As definitive treatment for hypersplenism or as a cytoreduction strategy before planned splenectomy in massive splenomegaly, SAE reduces splenic size, platelet consumption, and operative blood loss.
• Disease-specific Targeted Therapies: Hairy cell leukaemia now treated with cladribine; Gaucher disease managed with imiglucerase enzyme replacement — both have largely replaced splenectomy for their respective indications.